Cargando…

Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection

GPR40 mediates free fatty acid–induced insulin secretion in beta cells. We investigated the safety, pharmacokinetics, and glucose response of MK‐8666, a partial GPR40 agonist, after once‐daily multiple dosing in type 2 diabetes patients. This double‐blind, multisite, parallel‐group study randomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krug, AW, Vaddady, P, Railkar, RA, Musser, BJ, Cote, J, Ederveen, AGH, Krefetz, DG, DeNoia, E, Free, AL, Morrow, L, Chakravarthy, MV, Kauh, E, Tatosian, DA, Kothare, PA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593169/ https://www.ncbi.nlm.nih.gov/pubmed/28727908 http://dx.doi.org/10.1111/cts.12479

Ejemplares similares

Transcriptome profiling of Lactococcus lactis subsp. cremoris CECT 8666 in response to agmatine
por: del Rio, Beatriz, et al.
Publicado: (2015)

Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations
por: An, Xiaoli, et al.
Publicado: (2021)

Transcriptomic profile of aguR deletion mutant of Lactococcus lactis subsp. cremoris CECT 8666
por: del Rio, Beatriz, et al.
Publicado: (2015)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
por: Printz, Marie A., et al.
Publicado: (2020)

Genome Sequence Analysis of the Biogenic Amine-Producing Strain Lactococcus lactis subsp. cremoris CECT 8666 (Formerly GE2-14)
por: Ladero, Victor, et al.
Publicado: (2014)

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men
por: Tsuchiya, Saori, et al.
Publicado: (2016)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
por: Heske, Christine M., et al.
Publicado: (2016)

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
por: Hauge, Sissel, et al.
Publicado: (2019)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
por: Ahn, Daniel H., et al.
Publicado: (2015)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
por: Cook, Natalie, et al.
Publicado: (2018)

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017)

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis
por: Gordon, David, et al.
Publicado: (2023)

1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
por: Aliprantis, Antonios, et al.
Publicado: (2018)

Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
por: Yang, Bangkun, et al.
Publicado: (2016)

The acid–base and redox properties of menaquinone MK-4, MK-7, and MK-9 (vitamin K(2)) in DMPC monolayers on mercury
por: Dharmaraj, Karuppasamy, et al.
Publicado: (2020)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016)

Synchro Clock MkIV
por: Odier, P, et al.
Publicado: (2010)

Crucial Roles of the Protein Kinases MK2 and MK3 in a Mouse Model of Glomerulonephritis
por: Guess, Adam J., et al.
Publicado: (2013)

Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2
por: Gurgis, FMS, et al.
Publicado: (2015)

Cooperative and distinct functions of MK2 and MK3 in the regulation of the macrophage transcriptional response to lipopolysaccharide
por: Ehlting, Christian, et al.
Publicado: (2019)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

MK571 inhibits phase-2 conjugation of flavonols by Caco-2/TC7 cells, but does not specifically inhibit their apical efflux()
por: Barrington, Robert D., et al.
Publicado: (2015)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

GROWTH CHARACTERISTICS OF MONKEY KIDNEY CELL STRAINS LLC-MK(1), LLC-MK(2), AND LLC-MK(2)(NCTC-3196) AND THEIR UTILITY IN VIRUS RESEARCH
por: Hull, R. N., et al.
Publicado: (1962)

Analysis of growth-phase regulated genes in Streptococcus agalactiae by global transcript profiling
por: Sitkiewicz, Izabela, et al.
Publicado: (2009)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
por: Hudis, Clifford, et al.
Publicado: (2013)

A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase
por: Sakurikar, Nandini, et al.
Publicado: (2015)

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
por: Connor, Kathryn M., et al.
Publicado: (2016)

1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
por: Maas, Brian, et al.
Publicado: (2018)

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
por: Gordon, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_93f4p09409a64ki68060ctmlpn